Physician profile
Bhargav M Mistry
NPI 1033136676
$15,989.52
in general payments reported to CMS, 2019-2025
19 companies · $2,010 in 2025
The $2,010 reported for 2025 was more than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,648 · 2020: $95.76 · 2021: $723 · 2022: $6,425 · 2023: $3,455 · 2024: $1,632 · 2025: $2,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,096 · Food and Beverage: $964 · Education: $37.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,095.67 |
| Food and Beverage | $963.72 |
| Education | $37.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,622.11 | 2021-2024 | Ellipsys Vascular Access System, Interstim |
| Axonics, INC. | $2,270.13 | 2022 | |
| Transmedics, INC. | $2,065.25 | 2023 | Organ Care System |
| Globus Medical, INC. | $1,961.27 | 2025 | Excelsius Gps, Xlif |
| Medtronic USA, INC. | $1,708.36 | 2019-2020 | |
| Medical Device Business Services, INC. | $1,589.80 | 2022 | |
| Becton, Dickinson and Company | $963.69 | 2024 | Phasix Mesh |
| Davol INC. | $432.34 | 2024 | Phasix Mesh |
| Bard Peripheral Vascular, INC. | $91.74 | 2021-2022 | |
| Enterra Medical, INC. | $55.22 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.30 | 2022-2024 | Livtencity |
| Histosonics, INC. | $33.49 | 2025 | |
| Xvivo Perfusion INC. | $29.32 | 2024 | Xvivo Perfusion System (Xps) |
| Sanofi-Aventis U.S. LLC | $25.15 | 2024 | |
| Veloxis Pharmaceuticals, INC. | $25.11 | 2024 | Envarsus |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $22.88 | 2020 | |
| Novartis Pharmaceuticals Corporation | $22.42 | 2024 | |
| Kerecis Limited | $15.50 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Novo Nordisk INC | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhargav Mistry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.